The company said it saw record-setting growth in new products in fiscal 2018 with increasing reimbursement adding to its hereditary cancer business.
Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.
Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.
According to Myriad, a similar deal is in the works with the pharmacy benefit management services provider for its GeneSight pharmacogenetic test.
The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.
Mother Jones reports that some data used for interpreting what BRCA1 or BRCA2 mutations mean are kept private.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.